Antiviral efficacy of favipiravir against Zika and SARS-CoV-2 viruses in non-human primates

Efficacy of favipiravir in adults with mild COVID-19: a randomized, double-blind, multicentre, placebo-controlled clinical trial

(2022) Mohammad Bosaeed et al.   CLINICAL MICROBIOLOGY AND INFECTION

Favipiravir for treatment of outpatients with asymptomatic or uncomplicated COVID-19: a double-blind randomized, placebo-controlled, phase 2 trial

(2022) Marisa Holubar et al.   CLINICAL INFECTIOUS DISEASES

COVID-19 and liver disease

(2022) Jean-François Dufour et al.   GUT

SARS-CoV-2 infection and liver involvement

(2022) Mingjia Luo et al.   Hepatology International

Mechanisms of SARS-CoV-2 Infection-Induced Kidney Injury: A Literature Review

(2022) Weihang He et al.   Frontiers in Cellular and Infection Microbiology

Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection

(2021) Philip J.M. Brouwer et al.   CELL

Lassa viral dynamics in non-human primates treated with favipiravir or ribavirin

(2021) Guillaume Lingas et al.   PLoS Computational Biology

Understanding the pharmacokinetics of Favipiravir: Implications for treatment of influenza and COVID-19

(2021) Michael G. Ison et al.   EBioMedicine

The anti-influenza virus drug favipiravir has little effect on replication of SARS-CoV-2 in cultured cells

(2021) Yuriko Tomita et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model

(2021) Jean-Sélim Driouich et al.   Nature Communications

An AAV-based, room-temperature-stable, single-dose COVID-19 vaccine provides durable immunogenicity and protection in non-human primates

(2021) Nerea Zabaleta et al.   Cell Host & Microbe

Targeting SARS-CoV-2 receptor-binding domain to cells expressing CD40 improves protection to infection in convalescent macaques

(2021) Romain Marlin et al.   Nature Communications

Efficacy and Safety of Favipiravir in Moderate COVID-19 Pneumonia Patients without Oxygen Therapy: A Randomized, Phase III Clinical Trial

(2021) Masaharu Shinkai et al.   Infectious Diseases and Therapy

COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models

(2021) Pauline Maisonnasse et al.   Nature Communications

The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model

(2021) Rana Abdelnabi et al.   EBioMedicine

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

(2020) Manli Wang et al.   CELL RESEARCH

Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs

(2020) Sangeun Jeon et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection

(2020) Xin Zou et al.   Frontiers of Medicine

AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial

(2020) Andrey A Ivashchenko et al.   CLINICAL INFECTIOUS DISEASES

Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates

(2020) Pauline Maisonnasse et al.   NATURE

Extrapulmonary manifestations of COVID-19

(2020) Aakriti Gupta et al.   NATURE MEDICINE

In vitro evaluation of antiviral activity of single and combined repurposable drugs against SARS-CoV-2

(2020) Andrés Pizzorno et al.   ANTIVIRAL RESEARCH

Favipiravir at high doses has potent antiviral activity in SARS-CoV-2−infected hamsters, whereas hydroxychloroquine lacks activity

(2020) Suzanne J. F. Kaptein et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Rapid incorporation of Favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis

(2020) Ashleigh Shannon et al.   Nature Communications

Efficacy of favipiravir (T-705) in nonhuman primates infected with Ebola virus or Marburg virus

(2018) Sandra L. Bixler et al.   ANTIVIRAL RESEARCH

Antiviral efficacy of favipiravir against Ebola virus: A translational study in cynomolgus macaques

(2018) Jérémie Guedj et al.   PLOS MEDICINE

Zika plasma viral dynamics in nonhuman primates provides insights into early infection and antiviral strategies

(2017) Katharine Best et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted

(2017) Thi Huyen Tram Nguyen et al.   PLoS Neglected Tropical Diseases

Galidesivir, a Direct-Acting Antiviral Drug, Abrogates Viremia in Rhesus Macaques Challenged with Zika Virus

(2017) So-Yon Lim et al.   Open Forum Infectious Diseases

Favipiravir Pharmacokinetics in Nonhuman Primates and Insights for Future Efficacy Studies of Hemorrhagic Fever Viruses

(2016) Vincent Madelain et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Ebola Virus Infection: Review of the Pharmacokinetic and Pharmacodynamic Properties of Drugs Considered for Testing in Human Efficacy Trials

(2016) Vincent Madelain et al.   CLINICAL PHARMACOKINETICS

Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea

(2016) Daouda Sissoko et al.   PLOS MEDICINE

Biology of Zika Virus Infection in Human Skin Cells

(2015) Rodolphe Hamel et al.   JOURNAL OF VIROLOGY

Biopharmaceutical Characterization of Nebulized Antimicrobial Agents in Rats: 2. Colistin

(2014) Aline Vidal Lacerda Gontijo et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY